Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016
Published Jun 30, 2016
92 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016, provides in depth analysis on Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-

  
Source:
Document ID
GMDHC0209TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Overview81
Therapeutics Development94
  Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Stage of Development91
  Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Therapy Area101
  Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Indication112
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Companies155
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Universities/Institutes202
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Therapeutics Assessment226
  Assessment by Monotherapy/Combination Products221
  Assessment by Mechanism of Action231
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Companies Involved in Therapeutics Development2810
  Beta Pharma, Inc.281
  Eli Lilly and Company291
  G1 Therapeutics, Inc.301
  Jiangsu Hengrui Medicine Co., Ltd.311
  Novartis AG321
  Onconova Therapeutics, Inc.331
  Pfizer Inc.341
  Sihuan Pharmaceutical Holdings Group Ltd.351
  Teijin Pharma Limited361
  ViroStatics srl371
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Drug Profiles3836
  abemaciclib Drug Profile385
  BPI-1178 Drug Profile431
  FLX-925 Drug Profile441
  G-1T28 Drug Profile452
  G-1T38 Drug Profile471
  GZ-381 Drug Profile481
  MMD-37K Drug Profile491
  ON-123300 Drug Profile501
  palbociclib Drug Profile5110
  ribociclib succinate Drug Profile614
  SHR-6390 Drug Profile651
  Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis Drug Profile661
  Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer Drug Profile671
  Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer Drug Profile681
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile691
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections Drug Profile701
  Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology Drug Profile711
  Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile721
  Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology Drug Profile731
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Dormant Projects741
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Discontinued Products751
Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Featured News &Press Releases7615
  Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy761
  May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data771
  May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types771
  May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO781
  May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer791
  May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer801
  Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting811
  Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib)821
  Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting831
  Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting841
  Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows842
  Mar 07, 2016: New therapeutic target in myeloma discovered861
  Mar 02, 2016: Drug combination slows breast cancer spread871
  Feb 19, 2016: Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer882
  Dec 29, 2015: New breast cancer drug may be effective against other types of cancer901
Appendix912
  Methodology911
  Coverage911
  Secondary Research911
  Primary Research911
  Expert Panel Validation911
  Contact Us911
  Disclaimer921

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-6-Cell-Division-Protein-Kinase-6-or-EC-2-7-11-22-Pipeline-Review-H1-2016-2088-16101>
  
APA:
Global Markets Direct - Market Research. (2016). Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cyclin-Dependent-Kinase-6-Cell-Division-Protein-Kinase-6-or-EC-2-7-11-22-Pipeline-Review-H1-2016-2088-16101>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.